Eliglustat

(Cerdelga®)

Eliglustat

Drug updated on 11/9/2023

Dosage FormCapsule (oral: 84 mg)
Drug ClassGlucosylceramide synthase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test

Product Monograph / Prescribing Information

Document TitleYearSource
Cerdelga (eliglustat) Prescribing Information.2022Sanofi

Systematic Reviews / Meta-Analyses